Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
Follow CRL
Alert me
Charles River Laboratories International, Inc. 10-Q filed Aug 6, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 7, 2025: 22 added · 3 removed · 28 modified; 14 with only figures updated; 6 moved without change
-
Modified · U.S. Government Investigations into the Non-Human Primate Supply Chain
On February 17, 2023, we received a grand jury subpoena requesting certain documents related to an investigation by the U.S. Department of Justice (DOJ) and the U.S. Fish and Wildlife Service (USFWS) into our conduct regarding several shipments of non-human primates from Cambodia
. That investigation remains ongoingin late 2022 andwe are continuing to cooperate withearly 2023 (theinvestigationNHP Shipments).AsThe DOJ alsopreviously disclosed,undertook a parallel civil investigationis being undertaken byrelated to theDOJ and USFWSNHP Shipments.We are also cooperating with that investigation, and although we continue to disputeAs previously disclosed, we continued to care for the NHP Shipments during themeritspendency ofcertain positions taken bythe DOJ investigations. In July 2025, we were informed that USFWS had determined to clear theDOJNHP Shipments